18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 3, 2012, Pages 463-473

  Kiesewetter, Dale O ^a   Gao, Haokao ^a,b   Ma, Ying ^a   Niu, Gang ^a   Quan, Qimeng ^a   Guo, Ning ^a   Chen, Xiaoyuan ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

18F; Exendin 4; GLP 1R; Insulinoma; PET

Indexed keywords

CYSTINE; EXENDIN 4; FLUORINE 18; GLUCAGON LIKE PEPTIDE 1; MALEIMIDE DERIVATIVE; N [2 (4 FLUOROBENZAMIDO)ETHYL]MALEIMIDE; RADIOLIGAND; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; FLUORINE; PEPTIDE; VENOM;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG SPECIFICITY; DRUG STABILITY; DRUG SYNTHESIS; DRUG UPTAKE; FEMALE; HUMAN; IN VITRO STUDY; INSULINOMA; INTERNALIZATION; ISOTOPE LABELING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; TUMOR MODEL; TUMOR XENOGRAFT; AMINO ACID SEQUENCE; ANIMAL; BLOOD; CELL TRANSFORMATION; CHEMISTRY; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; PATHOLOGY; RAT; SCINTISCANNING; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DRUG STABILITY; FEMALE; FLUORINE RADIOISOTOPES; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULINOMA; MICE; MOLECULAR SEQUENCE DATA; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RATS; VENOMS;

EID: 84859640209     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1980-0     Document Type: Article

References (29)

1. Holst JJ, Deacon CF, Vilsboll T, Krarup T, Madsbad S. Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol Med. 2008;14:161-8.
2. Aaboe K, Krarup T, Madsbad S, Holst JJ. GLP-1: physiological effects and potential therapeutic applications. Diabetes Obes Metab. 2008;10:994-1003.
3. Tornehave D, Kristensen P, Romer J, Knudsen LB, Heller RS. Expression of the GLP-1 receptor in mouse, rat, and human pancreas. J Histochem Cytochem. 2008;56:841-51.
4. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in-vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in-vivo. J Clin Endocrinol Metab. 1995;80:952-7.
5. Mukai E, Toyoda K, Kimura H, Kawashima H, Fujimoto H, Ueda M, et al. GLP-1 receptor antagonist as a potential probe for pancreatic beta-cell imaging. Biochem Biophys Res Commun. 2009;389:523-6.
6. Wu Z, Kandeel F. Radionuclide probes for molecular imaging of pancreatic beta-cells. Adv Drug Deliv Rev. 2010;62:1125-38.
7. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003;30:781-93. (Pubitemid 36612963)
8. Hohmeier HE, Mulder H, Chen G, Henkel-Rieger R, Prentki M, Newgard CB. Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion. Diabetes. 2000;49:424-30. (Pubitemid 30131788)
9. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004;117:77-88. (Pubitemid 38045329)
10. Wild D, Behe M, Wicki A, Storch D, Waser B, Gotthardt M, et al. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med. 2006;47:2025-33. (Pubitemid 47558899)
11. Wild D, Wicki A, Mansi R, Behe M, Keil B, Bernhardt P, et al. Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT. J Nucl Med. 2010;51:1059-67.
12. Brom M, Oyen WJ, Joosten L, Gotthardt M, Boerman OC. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. Eur J Nucl Med Mol Imaging. 2010;37:1345-55.
13. Gotthardt M, Fischer M, Naeher I, Holz JB, Jungclas H, Fritsch HW, et al. Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. Eur J Nucl Med Mol Imaging. 2002;29:597-606. (Pubitemid 34439319)
14. Wicki A, Wild D, Storch D, Seemayer C, Gotthardt M, Behe M, et al. [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clin Cancer Res. 2007;13:3696-705. (Pubitemid 46955134)
15. Wild D, Macke H, Christ E, Gloor B, Reubi JC. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N Engl J Med. 2008;359:766-8.
16. Christ E, Wild D, Forrer F, Brandle M, Sahli R, Clerici T, et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab. 2009;94:4398-405.
17. Pattou F, Kerr-Conte J, Wild D. GLP-1-receptor scanning for imaging of human beta cells transplanted in muscle. N Engl J Med. 2010;363:1289-90.
18. Gao H, Niu G, Yang M, Quan Q, Ma Y, Murage E, et al. PET of insulinoma using 18F-FBEM-EM3106B, a new GLP-1 analog. Mol Pharm. 2011;8:1775-82.
19. Murage EN, Gao G, Bisello A, Ahn JM. Development of potent glucagon-like peptide-1 agonists with high enzyme stability via introduction of multiple lactam bridges. J Med Chem. 2010;53:6412-20.
20. Cai W, Zhang X, Wu Y, Chen X. A thiol-reactive F-18-labeling agent, N-[2-(4-F-18-fluorobenzamido)ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of αvβ3 integrin expression. J Nucl Med. 2006;47:1172-80. (Pubitemid 47544912)
21. Kiesewetter DO, Jacobson O, Lang L, Chen X. Automated radiochemical synthesis of [18F]FBEM: a thiol reactive synthon for radiofluorination of peptides and proteins. Appl Radiat Isot. 2011;69:410-4.
22. Chambers AF. MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res. 2009;69:5292-3.
23. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-5.
24. Grieve DJ, Cassidy RS, Green BD. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol. 2009;157:1340-51.
25. Kiesewetter DO, Kramer-Marek G, Ma Y, Capala J. Radiolabeling of HER2 specific Affibody® molecule with F-18. J Fluor Chem. 2008;129:799-805.
26. Froelich JM, Reid GE. The origin and control of ex vivo oxidative peptide modifications prior to mass spectrometry analysis. Proteomics. 2008;8:1334-45. (Pubitemid 351518546)
27. Hargrove DM, Kendall ES, Reynolds JM, Lwin AN, Herich JP, Smith PA, et al. Biological activity of AC3174, a peptide analog of exendin-4. Regul Pept. 2007;141:113-9. (Pubitemid 46482688)
28. Chen J, Yu L, Wang L, Fang X, Li L, Li W. Stability of synthetic exendin-4 in human plasma in vitro. Protein Pept Lett. 2007;14:19-25. (Pubitemid 46046948)
29. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem. 1993;268:19650-5. (Pubitemid 23270754)